Gene therapy using FGFR-inhibiting vector against lung squamous cell carcinoma

我们进行了一项利用FGFR抑制载体的基因治疗肺鳞癌的新治疗方法的实验研究。首先，我们对FGFR家族基因在肿瘤内的表达进行了临床研究。因此，我们认为不仅FGFR 1，而且FGR 2也可以作为治疗的靶基因。我们使用腺病毒载体（Ad-shFGFR 2）产生FGFR 2抑制载体。使用Ad-shFGFR 2对具有高FGFR 2表达水平的肺癌细胞系A549进行体外实验。Ad-shFGFR 2有效地敲低FGFR 2表达（约85%）。MTT法显示Ad-shFRFR 2对肿瘤细胞生长无明显抑制作用。因此，考虑到FGFR 2可能不是一个简单的驱动基因，我们使用与其他候选驱动基因共转染进行实验研究。

We performed an experimental study on the gene therapy using a FGFR-inhibiting vector for a new treatment against lung squamous cell carcinomas. First, we have done a clinical study on the inntratumoral expressions of FGFR family genes. Consequently, we considered that not only FGFR1 but also FGR2 could be target genes for treatments. We produced a FGFR2-inhibiting vector using an adenoviral vector (Ad-shFGFR2). in vitro experiments using the Ad-shFGFR2 were performed against a lung cancer cell line A549, which has high expression levels of FGFR2. The Ad-shFGFR2 effectively knocked down the FGFR2 expression (approximately 85%). However, MTT assays revealed that the Ad-shFRFR2 did not effectively inhibit the growth of tumor cells. Therefore, considering that FGFR2 may not be a simple driver gene, we perform an experimental study using co-transfection with other candidates of driver genes.